Amygdala Neurons In Dementia With Lewy Bodies is a cell type relevant to neurodegenerative disease research. This page covers its role in brain function, involvement in disease processes, and significance for therapeutic strategies.
The amygdala is particularly vulnerable in Dementia with Lewy Bodies (DLB), exhibiting Lewy body pathology that significantly impacts emotional processing, memory encoding, and autonomic function. The amygdala's extensive connections with the basal forebrain, hippocampus, and brainstem nuclei make it a critical hub for understanding DLB pathogenesis. [@yoshida2020]
¶ Lewy Body Distribution
In DLB, the amygdala demonstrates: [@beach2009]
- Amygdala-dominant Lewy body pattern: Concentrated alpha-synuclein inclusions in the amygdala corticomedullary nuclei
- Neuronal loss: Progressive degeneration of GABAergic and glutamatergic neurons
- Pathology spread: From the amygdala to cortical regions and brainstem nuclei
- Corticomedullary neurons: Most severely affected, containing dense Lewy body inclusions
- Basolateral amygdala pyramidal neurons: Vulnerable to Lewy body pathology
- Centromedial amygdala neurons: Affected early in DLB progression
Amygdala dysfunction in DLB contributes to: [@fujishiro2008]
- Mood disturbances: Depression, anxiety, and apathy
- Emotional blunting: Reduced emotional responsiveness
- Fear processing deficits: Impaired threat recognition
The central nucleus of the amygdala projects to autonomic centers, contributing to: [@halliday2014]
- Orthostatic hypotension
- Urinary dysfunction
- Gastrointestinal dysmotility
| Neurotransmitter |
Change |
Impact |
| GABA |
↓↓ |
Anxiety, seizure susceptibility |
| Glutamate |
↓ |
Cognitive impairment |
| Serotonin |
↓ |
Depression, mood disorders |
| Norepinephrine |
↓↓ |
Autonomic dysfunction |
The study of Amygdala Neurons In Dementia With Lewy Bodies has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Tsuang D et al., Amygdala pathology in Dementia with Lewy Bodies (2012)
- Yoshida M et al., Amygdala involvement in Lewy body disease (2020)
- Beach TG et al., Organization of the Amygdala in Dementia with Lewy Bodies (2009)
- Fujishiro H et al., Amygdala alpha-synuclein pathology in DLB (2008)
- Halliday GM et al., Amygdala in Lewy body disease (2014)
- Sorrentino ZA et al., Unique alpha-synuclein pathology within the amygdala in Lewy body dementia (2019)
- Gawor K et al., Amygdala-predominant alpha-synuclein pathology is associated with exacerbated hippocampal neuron loss in Alzheimer's disease (2024)
- Popescu A et al., Lewy bodies in the amygdala: increase of alpha-synuclein aggregates in neurodegenerative diseases with tau-based inclusions (2004)
- Borghammer P et al., Neuropathological evidence of body-first vs. brain-first Lewy body disease (2021)
- Cersosimo MG., Propagation of alpha-synuclein pathology from the Olfactory Bulb (2018)
- Kim S et al., Transneuronal Propagation of Pathologic alpha-Synuclein from the Gut to the Brain Models Parkinson's Disease (2019)
- Levin J et al., alpha-Synuclein seed amplification assay detects Lewy body co-pathology in autosomal dominant Alzheimer's disease (2024)
- van Wetering J et al., Neuroinflammation is associated with Alzheimer's disease co-pathology in dementia with Lewy bodies (2024)
- van der Gaag BL et al., Distinct tau and alpha-synuclein molecular signatures in Alzheimer's disease with and without Lewy bodies (2024)
- Saito Y et al., Neuropathology of amygdala in Lewy body disease (2011)